TG Therapeutics, Inc.

Symbol: 0VGI.L




Market price today

  • -94.8845

    P/E Ratio

  • -6.4187

    PEG Ratio

  • 2.38B

    MRK Cap

  • 0.00%

    DIV Yield

TG Therapeutics, Inc. (0VGI-L) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Pharmaceuticals, Biotechnology & Life Sciences
CEO:Mr. Michael S. Weiss Esq.
Full-time employees:245
City:New York
Address:2 Gansevoort Street

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

General Outlook

In simple terms, TG Therapeutics, Inc. has 151.41 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.967% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.100%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.137%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.078% return, is a testament to TG Therapeutics, Inc.'s adeptness in optimizing resource deployment. TG Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.356%. Furthermore, the proficiency of TG Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.069% return on capital employed.

Stock Prices

TG Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $13.59, while its low point bottomed out at $12.39. This variance in figures offers investors a lucid insight into the roller-coaster ride that is TG Therapeutics, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of TG Therapeutics, Inc. (0VGI.L) on the LSE in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -94.885 in 2023.

What is the ticker symbol of TG Therapeutics, Inc. stock?

The ticker symbol of TG Therapeutics, Inc. stock is 0VGI.L.

What is company IPO date?

IPO date of TG Therapeutics, Inc. is 2018-11-23.

What is company current share price?

Current share price is 15.750 USD.

What is stock market cap today?

The market cap of stock today is 2384707500.000.

What is PEG ratio in 2023?

The current -6.419 is -6.419 in 2023.

What is the number of employees in 2023?

In 2023 the company has 245.